<DOC>
	<DOCNO>NCT00359801</DOCNO>
	<brief_summary>The purpose study evaluate long-term pulmonary cardiovascular safety Exubera routine clinical practice .</brief_summary>
	<brief_title>Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing Exubera . At time , Pfizer commit continue marketing return license right technology Nektar . Following announcement , enrollment halt . Subjects already enrol receive treatment time halt enrollment could continue study accordance protocol . Nektar , company Pfizer license Exubera , announce April 9 , 2008 stop search new marketing partner . Accordingly , commercial availability Exubera . As result , amendment file April 16 , 2008 specify subject randomize Exubera transition usual diabetes care , study subject follow serious adverse event 6 month . In accordance amendment , study A2171069 terminate April 29 , 2009 . Neither safety efficacy reason cause study termination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Eligible receive Exubera treatment base approve local label Pregnant lactating Have progressive fatal disease life expectancy prohibit participate fiveyear research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Large Simple Trial</keyword>
</DOC>